HealthDay News — For premenopausal women with breast cancer, chemotherapy plus the luteinizing hormone-releasing hormone analogue (LHRHa) triptorelin is associated with higher long-term probability of ovarian function recovery, according to a study published in the Dec. 22/29 issue of the Journal of the American Medical Association.

Matteo Lambertini, MD, from the Istituto Nazionale per la Ricerca sul Cancro in Genova, Italy, and colleagues examined the long-term results of LHRHa-induced ovarian suppression during breast cancer chemotherapy. Two hundred eighty-one premenopausal women with stage I to III hormone-receptor positive or hormone-receptor negative breast cancer were enrolled and randomized to chemotherapy plus LHRHa (148 patients) or chemotherapy alone (control; 133 patients). Participants were followed for a median of 7.3 years.

The researchers found that the five-year cumulative incidence estimate of menstrual resumption was 72.6% in the LHRHa group and 64.0% in the control group (hazard ratio [HR], 1.28; 95% confidence interval [CI], 0.98 to 1.68; P=0.07; age-adjusted HR, 1.48; 95% CI, 1.12 to 1.95; P=0.006). The five-year cumulative incidence of pregnancy was 2.1 and 1.6% in the LHRHa and control groups, respectively (HR, 2.56; 95% CI, 0.68 to 9.60; P=0.14; age-adjusted HR, 2.40; 95%  CI, 0.62 to 9.22; P=0.20).

“Concurrent administration of triptorelin and chemotherapy, compared with chemotherapy alone, was associated with higher long-term probability of ovarian function recovery, without a statistically significant difference in pregnancy rate,” the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)